27 Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability 1 after the first injection and was therefore included for analysis. Nine children were excluded because of a progressive condition or unknown first or second dosage of onabotulinum A injection. In total, 77 children were included in the analysis (mean age 8y 3mo, SD 3y 7mo, range 3-17y; 44 males, 33 females). Twenty-four children (31.2%) had an identical third onabotulinum neurotoxin A injection as well (Table 1). Out of the 356 drooling quotient and VAS measurements, there were 29 (8.1%) missing values for drooling quotient and 29 (8.1%) missing values for VAS. The mean drooling quotient and VAS scores per assessment are shown in Figure 1. Table 1: Baseline patient demographics Patient characteristic n (%) Age, mean, SD (range), y:mo 8:3, 3:7 (3–17) Sex Male 44 (57.1) Female 33 (42.9) Main diagnosis Cerebral palsy 40 (51.9) Non-cerebral palsya 37 (48.1) Degree of disabilityb Ambulant 42 (54.5) Non-ambulant 35 (45.5) Developmental age <4y 49 (63.6) >4y 28 (36.4) Epilepsy Diagnosed with epilepsy 42 (54.5) No epilepsy 35 (45.5) Type of injection Submandibular 72 (93.5) Submandibular and parotid 5 (6.5) aNon-cerebral palsy consisted mainly of developmental disorders based on a syndrome, metabolic, or genetic disorder. bThe degree of disability in children with cerebral palsy was based on the Gross Motor Function Classification System (GMFCS). A GMFCS level of I–III was classified as ambulant and a GMFCS level of IV–V was classified as non-ambulant.
RkJQdWJsaXNoZXIy MjY0ODMw